Compare RDNT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | RYTM |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.4B |
| IPO Year | 1986 | 2017 |
| Metric | RDNT | RYTM |
|---|---|---|
| Price | $72.40 | $112.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $83.60 | ★ $125.77 |
| AVG Volume (30 Days) | 837.5K | ★ 887.7K |
| Earning Date | 11-09-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,969,599,000.00 | $174,334,000.00 |
| Revenue This Year | $11.77 | $47.34 |
| Revenue Next Year | $10.76 | $57.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.09 | ★ 54.92 |
| 52 Week Low | $45.00 | $45.91 |
| 52 Week High | $85.84 | $122.20 |
| Indicator | RDNT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 58.29 |
| Support Level | $74.96 | $109.59 |
| Resistance Level | $79.67 | $122.20 |
| Average True Range (ATR) | 3.07 | 5.23 |
| MACD | -0.87 | 1.08 |
| Stochastic Oscillator | 19.10 | 56.83 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.